問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Digestive System Department

更新時間:2023-09-19

蘇育正Su, Yu-Chung
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

篩選

List

13Cases

2019-09-30 - 2021-07-27

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2016-10-10 - 2022-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting3Sites

Terminated3Sites

2018-04-01 - 2020-04-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2018-04-01 - 2020-04-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2018-04-01 - 2020-04-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2018-11-01 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis
  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
6Sites

Recruiting2Sites

Terminated2Sites

2016-08-01 - 2020-12-31

Others

Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease
  • Condition/Disease

    Ulcerative Colitis and Crohn’s Disease

  • Test Drug

    Vedolizumab IV

Participate Sites
2Sites

Terminated1Sites

2018-10-01 - 2020-08-25

Phase II

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis
  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib (GS-6034)

Participate Sites
7Sites

Terminated6Sites

2017-02-17 - 2020-12-17

Phase III

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting8Sites

Terminated3Sites

1 2